Impact Factor 3.675

The 2nd most cited open-access journal in Endocrinology & Metabolism

Original Research ARTICLE Provisionally accepted The full-text will be published soon. Notify me

Front. Endocrinol. | doi: 10.3389/fendo.2018.00114

Nontoxic Goiter and radioiodine: what do patients think about it? Quality of Life in Patients with NTG before and after 131-I therapy.

 Sonia Kaniuka-Jakubowska1*, Anna Lewczuk1, Krystyna Mizan-Gross2, Mikołaj Majkowicz3, Maciej Piskunowicz4, Adam Zapaśnik4, Piotr Lass2 and  Krzysztof Sworczak1
  • 1Department of Endocrinology and Internal Medicine, Medical University of Gdansk, Poland
  • 2Department of Nuclear Medicine, Gdańsk Medical University, Poland
  • 3Department for Quality of Life Research, Gdańsk Medical University, Poland
  • 4Department of Radiology, Gdańsk Medical University, Poland

Despite numerous publications regarding nontoxic goiter (NTG) treatment, and an increasing interest in patients’ quality of life, few studies present the outcome of 131-I treatment from the patients’ perspective. Our study’s main aim was to verify whether there is any improvement in life quality following131-I treatment.

35 patients with NTG qualified to participate in the study. All patients completed a Thyroid-Related Health-Related Quality of Life (Thy-R-HRQoL) questionnaire created by us and the Medical Outcomes Study 36-item Short Form (SF-36), right before and one year after 131- I.

We observed an improvement in 6 out of 8 SF-36, and 3 out of 7 Thy-R-HRQoL domains. In comparison with the control group, we observed worse results in 2 out of 8, prior to treatment, and 1 out of 8 of SF-36 afterwards, as well as in all Thy-R-HRQoL domains. We did not find any correlation between improvement of Thy-R-HRQoL and SF-36 and goiter size reduction, except for Bodily Pain. There was also no correlation between improvement of SF-36 and Thy-R-HRQoL domains, and goiter size before treatment. The older the patient, the less noticeable improvement was observed in Physical and Social Functioning, and Vitality in SF-36, but age had no influence on the assessment by Thy-R-HRQoL.

Radioiodine treatment improves life quality in patients with NTG. Use of the Health-Related Quality of Life questionnaire should be taken into consideration when evaluating life quality of patients with NTG. Relentless pursuit of maximal goiter size reduction in 131-I treatment is worth consideration. In our study, life quality improvement, did not depend directly on the goiter size reduction. Life quality improvement after 131-I might not depend on initial goiter size, and for certain domains of SF-36 might be less clearly expressed in older patients.

Keywords: Nontoxic goiter, radioiodine, Quality of Life, SF-36, Life quality

Received: 25 Nov 2017; Accepted: 07 Mar 2018.

Edited by:

Alessandro Antonelli, Università degli Studi di Pisa, Italy

Reviewed by:

Gabriela Brenta, Dr. César Milstein Care Unit, Argentina
MICHELE MINUTO, UO Chirurgia 1 Department of Surgery, IRCCS AOU San Martino IST Genova, Italy  

Copyright: © 2018 Kaniuka-Jakubowska, Lewczuk, Mizan-Gross, Majkowicz, Piskunowicz, Zapaśnik, Lass and Sworczak. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: MD, PhD. Sonia Kaniuka-Jakubowska, Department of Endocrinology and Internal Medicine, Medical University of Gdansk, Gdansk, Poland,